Sepracor Inc.

Patterson, PA: (Sep-10-07) Two securities class action lawsuits were brought against Sepracor Inc., a Massachusetts-based pharmaceutical company, alleging that it concealed safety concerns surrounding its new antihistamine candidate, Soltara, that was rejected by the FDA for marketing approval in March 2002.

In a settlement reached, Judge Morris Lasker of the US District Court for the District of Massachusetts granted final approval of a $52.5 million settlement, resolving the class actions. Sources claim that the settlement is the third-largest settlement in a securities fraud case against a bio-technology company concerning a drug approval. The suit was maintained by Staro Asset Management, LLC on behalf of a debt class consisting of holders of Sepracor's convertible debt securities, and by Westmont Venture Partners, LLC on behalf of an equity class consisting of holders of Sepracor's common stock, call options and put options. If the suit had gone to trial, experts say that there would have been a battle of conflicting medical and scientific experts given the multitude of complex scientific issues surrounding the development of Sepracor's new drug candidate. Additionally, economic experts would have quarreled about the proper measure of damages to the two classes caused by Sepracor's failure to obtain approval for its highly touted antihistamine drug. [CNN NEWS: SEPRACOR SECURITIES]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please fill in our form on the right.

Add Your Comment on This Issue

Please read our comment guidelines before posting.

Note: Your name will be published with your comment.

Your email will only be used if a response is needed.

Request Legal Help